Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of treatment with
subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The
target population for this study includes patients who meet the 2013 American College of
Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic
sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than
6 years from first non-Raynaud's phenomenon symptom.